Want to join the conversation?
$STZ lifted its FY17 EPS guidance to range of $6.25-6.40 from prior forecast of $5.98-6.28 and its comparable EPS outlook to range of $6.30-6.45 from prior range of $6.05-6.35. $STZ still sees FY17 interest expense of about $325-335MM, operating cash flow of about $1.5-1.7Bil, and tax rate of about 29%.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?